Alpha Teknova, Inc.

Q1 2023 Earnings Conference Call


spk00: Good day and welcome to the TechNOVA first quarter 2023 financial result call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Senior Vice President of Marketing at Technova, Jennifer Henry. Please go ahead. Thank you, Operator.
spk05: Welcome to Technova's first quarter of 2023 Earnings Conference Call. With me on today's call are Stephen Gunstream, Technova's President and Chief Executive Officer, and Matt Lowell, Technova's Chief Financial Officer, who will make prepared remarks and then take your questions. As a reminder, the forward-looking statements that we make during this call, including those regarding business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning these risk factors is included in the press release the company issued earlier today, and they are more fully described in the company's various filings with the SEC. Today's comments reflect the company's current views which could change as a result of new information, future events, or other factors, and the company does not obligate or commit itself to update its forward-looking statements except as required by law. The company's management believes that, in addition to GAAP results, non-GAAP financial measures can provide meaningful insight when evaluating the company's financial performance and the effectiveness of its business strategies. We will therefore use non-GAAP financial measures of certain of our results during this call. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this afternoon, which is posted to Technova's website and at Non-GAAP financial measures should always be considered only as a supplement to, and not as a substitute for, or as superior to, financial measures prepared in accordance with GAAP. The non-GAAP financial measures in this presentation may differ from similarly named non-GAAP financial measures used by other companies. Please also be advised that the company has posted a supplemental slide deck to accompany today's prepared remarks. It can be accessed on the investor relations section of Technova's website and on today's webcast. And now I will turn the call over to Stephen.
spk03: Thank you, Jen. Good afternoon and thank you everyone for joining us for our first quarter of 2023 Earnings Call. Technova is a leading producer of critical reagents for the life sciences industry to accelerate the introduction of novel therapies, vaccines, and molecular diagnostics that will help people live longer, healthier lives. We manufacture high-quality custom reagents with short turnaround times and are positioned to scale with our customers as they advance their products from discovery to commercialization. We had a good start to the year. Our team continued to manage in a dynamic environment by delivering results in line with our plan, including increasing revenue sequentially by 16%. We are particularly pleased that we are not only tracking well to our expected financial metrics for the year, but we are also executing on our key initiatives on or ahead to plan to position the company for sustainable, accelerated growth. First, we saw an increase in clinical solutions customers in the first quarter and believe the growth demonstrates a stabilization in overall demand from our customers, and we remain optimistic about the long-term potential of our target markets. We also continue to see strength in our commercial funnel and remain confident in our top-line guidance for the full year. Second, Our new state-of-the-art modular manufacturing facility is on track for GMP-grade production by mid-2023. In addition, we are encouraged by early indications of interest from certain of our customers who have begun to schedule audits for early in the third quarter. We believe this new facility, plus our existing operating infrastructure, will give us the capacity to deliver approximately $200 million in annual product revenue when fully utilized. On the R&D front, I am pleased to say our new product pipeline is progressing ahead of schedule. In March, we announced a collaboration with Sartorius via Separations to help our customers improve AAV purification processes. Building on this news, last week we launched our first ever set of proprietary agents, which we believe can save months of development time for gene therapy customers as they develop their AAV bioprocessing workflows. As customers incorporate these proprietary reagents into their clinical production processes, we expect to become an even more critical supplier as they advance their therapies towards commercialization. Lastly, we are tracking well to our cost reduction plans. Operational expenses were down sequentially when excluding one-time costs. And while cash outflow in the quarter was approximately $12 million, the corresponding expenses were planned and primarily related to the completion and qualification of our new facility. Thus, we are tracking towards our previously communicated total cash outflow target of approximately $30 million for fiscal 2023. I will now hand the call over to Matt for discussion of the financials.
spk04: Thanks, Stephen, and good afternoon, everyone. Total revenue was $9.1 million for the first quarter of 2023, an 18% decline from $11.1 million in the first quarter of 2022, reflecting the continued headwinds associated with lower demand from early-stage biopharma customers, which we first observed in the third quarter of 2022. Lab Essentials products are targeted at the research-use-only, or RUL, market. and include both catalog and custom products. Lab Essentials revenue was $7.3 million in the first quarter of 2023, a 4% increase from $7.0 million in the first quarter of 2022. Growth for the first quarter was primarily driven by higher average revenue per customer, partially offset by a decreased number of customers. Clinical Solutions products are made according to good manufacturing practices or GMP quality standards and are primarily used by our customers as components or inputs in the development and manufacture of diagnostic and therapeutic products. Clinical Solutions revenue was $1.6 million in the first quarter, a 58% decrease from $3.8 million in the first quarter of 2022. The decrease in clinical solutions revenue was attributable to lower average revenue per customer, partially offset by an increased number of customers. We expect revenue per customer to increase over time as they ramp up their purchase volumes. However, this metric can be affected by the mix of newer clinical customers who typically order less. Just as a reminder, due to the large average order sizes in clinical solutions compared to lab essentials, There can be quarter-to-quarter revenue lumpiness in this category. Gross profit for the first quarter of 2023 was $2.4 million compared to $5.3 million in the first quarter of 2022. Gross margin was 26.6 percent of revenue in the first quarter of 2023, which is down from 48 percent of revenue in the first quarter of 2022. The lower gross margin for the first quarter of 2023 compared to the first quarter of 2022 was primarily driven by the decrease in revenue and the associated lower absorption of fixed manufacturing labor and overhead costs, including depreciation from our new facility. Operating expenses for the first quarter of 2023 were $11.4 million, compared to $11.2 million for the first quarter of 2022. Excluding the one-time non-recurring charge related to the reduction in workforce of $0.7 million incurred during the first quarter of 2023, operating expenses decreased compared to the first quarter of 2022. The decrease was driven by reduced spending, primarily in professional fees and occupancy costs, partially offset by higher wages and stock-based compensation expense. The reduction in workforce of approximately 40 positions is expected to generate annualized savings of approximately $4 million. Net loss for the first quarter of 2023 was 8.8 million, or 31 cents per diluted share, compared to a net loss of 5.5 million, or 20 cents per diluted share, for the first quarter of 2022. The company recorded minimal tax benefit this quarter against its pre-tax losses, as it is currently recording valuation allowances against incremental net operating loss carried forwards. Adjusted EBITDA, a non-GAAP measure, was negative 6.1 million for the first quarter of 2023, compared to negative 4.3 million for the first quarter of 2022. However, adjusted EBITDA increased by more than $2 million sequentially. Capital expenditures for the first quarter of 2023 were 4.3 million compared to 5.9 million for the first quarter of 2022. This marks the third straight quarter of declining capital expenditures. Most of the spending in the first quarter of 2023 went towards the completion and qualification of our new GMP production facility. Free cash flow, a non-GAAP measure which we define as cash provided by or used in operating activities, less purchases of property, plant, and equipment, was negative $12.0 million for the first quarter of 2023 compared to negative 11.1 million for the first quarter of 2022. This decrease compared to the prior year period was primarily due to higher cash used in operating activities partially offset by a decrease in capital expenditures. Turning to the balance sheet, as of March 31st, 2023, we had $30.2 million in cash and cash equivalents and $22.1 million in gross debt. Now, onto our 2023 guidance and outlook. We are reiterating 2023 total revenue guidance of $42 million to $46 million. At the midpoint, this assumes revenue growth of approximately 6% compared to 2022. With respect to product categories, we continue to expect LabEssential's revenue to be roughly flat compared to 2022, and clinical solutions revenue to grow between 20% to 50% compared to 2022. This product category growth guidance includes the assumption that a significant customer shifts from lab essentials to clinical solutions products in 2023. The company continues to aggressively manage expenses. At the end of March, the company had 251 associates, down from 290 at the end of 2022. Excluding non-recurring charges, the company posted operating expenses below $11 million for the first time since 2021, which does not reflect the full benefit of the reduction in force completed in February. Similarly, the company saw a reduction in free cash outflow during the first quarter of 2023. This marks the third straight quarter of lower cash outflow and is consistent with the company's expectations for the year as we anticipate operating losses and capital expenditures to continue to trend downward over the course of the year. In addition to cash on hand, we have access to our revolver, up to $5 million, and ATM facility up to $14.5 million. Further, we believe we have already made the step-up investments needed to execute our growth strategy and can scale without significant additional investment. With that, I will turn the call back to Stephen.
spk03: Thanks, Matt. Overall, we were pleased with our performance in the first quarter of 2023. The long-term outlook for our end markets remains positive We are committed to executing on our strategy to help our customers accelerate the introduction of novel therapies, diagnostics, and other products that improve human health. We will now take your questions.
spk00: Thank you. As a reminder, to ask a question, please press star 1-1 on your telephone and wait for your name to be announced. To withdraw your questions, please press star 1-1 again. One moment for our first question. And that will come from the line of Jacob Johnson with Stevens. Your line is open.
spk01: Hey, good afternoon, Steven and Matt. Congrats on this quarter. Maybe just to kick it off with the lazy macro question, just because there's been a lot of mixed commentary this quarter about the cell and gene therapy space. I'd just be curious kind of if you're seeing any kind of hesitation from customers due to the macro. Certainly doesn't seem like it, given the result you put up, or at least maybe versus your prior expectations. And the year seems to be tracking ahead of plan. So maybe just start there on the macro.
spk03: Yeah, great. Thanks, Jacob. You know, we have not seen a decrease from what we called out after our 2-2 earnings in 2022. And I think that we are a little bit different than some of the other players in the space in that, you know, our reagents aren't stock right? We have a unique ability to custom manufacture these things and get them there quickly and so are not prone to some sort of besocking piece. But we are tied, obviously, to some of the biotech funding. So when we saw the biotech funding shift and impact that had in the back half of the year, what we saw was what we've reiterated before, which is a slowdown in the number of clinical trials happening or reduced in size of those clinical trials. And as I said in the last earnings call, we kind of believe we're in a kind of a new normal operating environment where the customers we're talking to now have their budget for the year and they're building that up. And you can see from what we just said in the script here that we have seen an increase in clinical customers in the first quarter. And we see that as a very positive sign that the funnel is building and that our commercial strategy is working and that should be paying off in the back half this year as we've indicated.
spk01: Got it. And then I guess the follow-up just on the AAV tech launch, that seems to be kind of the formal commercial launch of that product. I think you've been testing with customers. I'm curious about reception, especially given some of the disclosures today about the difficulties of the downstream chromatography steps.
spk03: Yeah, and I think it is a major pain point. From the time I started here in 2020, the first time we talked to some of these AAV gene therapy developers was really separating these empty and full capsids. And the team has done an awesome job of putting together a complete solution for those customers. We launched the AAV2 serotype kit a couple weeks ago, and in what marks really the first time that Tecmo has launched some proprietary products. The customer response has been very favorable, really excited. We're excited. The product's actually in stock, ready to go, and it's going to help us onboard a lot more of these customers and then get them into our reagents. And as they go downstream, they become bigger and more reliant on us as they go through commercialization. But probably most importantly for them, this is a lot of work from that step to identify which is the right set of buffers to do that last polishing step, and we can save them months of time of work to get them into the clinic faster.
spk01: Got it. Thanks, Stephen.
spk00: Thank you. One moment for our next question. And that will come from the line of Matt LaRue with William Blair. Your line is open.
spk06: Hi. Thank you so much for taking my question. This is actually Madeline Mullen. I'm for Matt. Thinking about the clinical solution step down year over year, I know you said that part of that was due to sort of a mix towards newer customers. Can you talk a little bit about how you see that trending over the year and what is kind of incorporated in your guidance for the year from Clinical Solutions?
spk03: Yeah, I'll start, Matt. Feel free to jump in. I mean, we've talked about the changes in the biotech funding space and the particular impact on early and mid-stage biotech. Particularly for us, we have a number of customers in cell and gene therapy. that were affected by that. And they reduced their overall size of clinical trial and the number of clinical trials or the number of different therapies working through the pipeline. And so we pulled that obviously out and it's built into the forecast for the year. And so not surprising, you know, these are right in line with what we'd expect to be, if not ahead after the first quarter. For the remainder of the year, though, We do have a commercial organization up and going, and we're excited to see that we've increased the number of clinical customers on a year-on-year. Yes, the average spending down, but that is expected. And we do think that the back half of this year, you know, they're lining up to be really well as we look at our funnel, and then obviously into 2024. Then you combine that with their new facility opening, and the facility will allow, obviously, a lot of capacity expansion, but also allows us to onboard some of these customers that now can look at our facility and realize that we can be with them all the way through commercialization and beyond. So, I mean, the combination of those two things, I think, sets us up really well for a strong back half year in 2024.
spk06: Great. Thank you. And so just thinking from a margin perspective, I think in the past you said that you were expecting full year margins to be around 30%. Does this change the clinical solutions piece, change anything about how you're thinking about margins for the year?
spk04: Yeah, I would just say from a margin perspective, I mean, for the full year, we've certainly mentioned about 30% range. You know, we've certainly considered the amount of clinical revenue contribution for the year and that into the margins. That's not really changing here, again, as we've kind of reiterated our guidance on revenue for the year. So I think we will see at times when the revenue from clinical is a bigger contributor in the quarter, it could be a help to margins. But generally speaking, the biggest help to gross margins is just overall revenue volume. So we're still seeing the current margins where they are, similar to last quarter. at this revenue level and with the new facility coming into play. But for the full year, we're still looking for the same type of result you mentioned, Maddie.
spk06: Thanks. I really appreciate it.
spk00: Thank you. One moment for our next question. That will come from the line of Stephen Ma with TD Cowan. Your line is open.
spk02: Great, thanks. Congrats on the quarter and thanks for taking the questions. A couple of follow-up ones on the AAV tech solutions kit. Did you guys do any voice of customer or other market research to identify this pain point in the AAV bioprocessing? And, you know, if you did, do you guys have a sense on how big the market opportunity is for this product given that it's so new?
spk03: Yeah, and it certainly is a new product, and it's a product that solves a problem from a number of our customers. So, yes, we did do market research, obviously talking to customers directly, but also additional market research on the product. Again, you know, the value driver of this is really over the long term, right? Instead of coming to us with this very specific formulation after they've done months of work to figure out what the right buffer combination is, to use to get their virus purified and polished, they can come right into our proprietary reagents and find a solution in a couple weeks. And so once they do that, then they're kind of using our reagents and they become bigger, larger trials as they move down the pipeline and ultimately commercialization. We think that the expansion in that timeframe from beginning to end is about a 30-fold increase. And this was actually some of the research we did even before we took the company public, was in this area, and feel pretty good about not only the size, and if you look at the size of the number of therapies going through AAV, that's one way to look at it, but also of one of the most critical pain points. I don't think we've yet disclosed the size of that market. I think it obviously depends on the number of trials that you assume that go through and the amount of spend, but maybe that's something we could do at a later date.
spk02: Okay, got it. And then... Could you just give me a sense for the kit, like, you know, how many assays or runs it would go through?
spk03: Yeah, so the kit itself – oh, sorry. I know, go ahead. The kit itself is built out of a number of what we call design of experiments done here internally. So we ran hundreds of different buffer combinations to basically set this – down to a size of about seven combination buffers, so 14 total in one liter bottles for customers to evaluate. So depending on the serotype they're using, the sort of the resin or the platform they're using for purification, as well as their transgene, you may end up choosing one of these seven buffers. So the idea is you get this whole kit in, you try all seven, and then identify which of those combinations will work for you. And then the customers can do a couple things. Obviously, they can continue to order one of those going forward. We sell those individually. They can order them in larger scale. They can order them in GMP format. They can also come back to us. We can do some work with them and find out if there's a combination between a couple of them that will even give them better results. It's really up to them to define, which is kind of what makes us unique, and then we can get these into production then for them and then scale with them through clinical trials.
spk02: Okay, that's real helpful. And then a question for Matt about the gross margin. So, you know, how should we think about the gross margin impact as your new facility comes online, you know, as a facility scales and you can spread out overhead and fixed costs? When do you expect the gross margins to sort of bottom out and then begin to recover? Thanks.
spk04: Yeah, I think, you know, overall the long-term story for gross margin is that we're targeting 60% to 65%, right? That's quite a bit of where we are today, but we expect to see some pretty good acceleration in that gross margin as we, you know, grow the top line as we're expecting here over the next several years. So, we do have that potential going forward. In the short run, there is going to be pressure on gross margins, as you pointed out, with the new facility in particular. Depreciation is one of the major costs that we have that are impacting the P&L. We started some depreciation on a portion of the facility at the very end of last year. We have a full quarter of that in Q1 results. And we'll be bringing more parts of the facility online later this year, which will load. But, you know, I think this year, FY23 will be the low point because of these added costs coming in. And as we grow the top line, we'll start to see some material improvements going forward.
spk02: Okay, great. That's very helpful. Thank you.
spk00: Thank you. I'm showing no further questions in the queue at this time. this concludes today's program thank you all for participating you may now disconnect

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.